Global Blood Therapeutics, Inc.

Amgen Inc.

Manuel Zancanella

Ming Yu

Zhe Li

Xianghong Wang

Sean P Brown

Marc Vimolratana

Yunxiao Li

Joshua Taygerly

Qing Xu

Liusheng Zhu

Ana Zurisadai Gonzalez Buenrostro

Zhihong Li

Mike Elias Lizarzaburu

Lina Quattrocchio Setti

Chul Yu

Hing L Sham

Brian Stuart Lucas

Calvin Wesley Yee

Nick A Paras

Julio Cesar Medina

Jonathan B Houze

Xuelei Yan

Michael G Johnson

Yosup Rew

Felix Gonzalez Lopez De Turiso

Alan C Cheng

Mario G Cardozo

Jason A Duquette

Kexue Li

Yingcai Wang

Todd J Kohn

Michael R Degraffenreid

Jiasheng Fu

Xian Yun Jiao

Michael W Gribble, Jr

Jiang Zhu

Shahul Nilar

David Karl Bedke

Mike Elias Lizazaburu

The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Tricyclic compounds as histone methyltransferase inhibitors

The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I: and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.

Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibit MCL-1 protein

The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Azaindole compounds as histone methyltransferase inhibitors

Provided herein are kallikrein modulating compounds, pharmaceutical compositions comprising the same, and uses thereof.

Bridged bicyclic kallikrein inhibitors

Compounds that inhibit Mcl-1 protein

Growing community of inventors

San Mateo, CA, United States of America

Manuel Zancanella